TruScreen Group Limited announced that the private medical services provider, Dr. Sulaiman Al-Habib Medical Group (DSAMG), has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC). A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen's sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 NZD | 0.00% |
|
0.00% | -21.74% |
May. 30 | TruScreen Group Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
May. 30 | Truscreen's Fiscal Year 2024 Loss Widens | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.74% | 6.08M | |
+6.80% | 216B | |
+11.10% | 189B | |
+27.66% | 153B | |
+33.06% | 114B | |
+1.71% | 63.2B | |
+18.98% | 54.78B | |
+1.63% | 48.47B | |
-2.72% | 38.88B | |
+2.64% | 36.14B |
- Stock Market
- Equities
- TRU Stock
- News TruScreen Group Limited
- TruScreen Group Limited Announces Clinical Evaluation Results from Saudi Arabia